Go to Content Go to Navigation Go to Navigation Go to Site Search Homepage

PPNNE Statement in Response to U.S. Supreme Court’s Announcement Regarding Medication Abortion Case 

For Immediate Release: Dec. 13, 2023


COLCHESTER, VT – Today, the Supreme Court of the United States announced it will consider a court challenge to the Federal Drug Administration's approval of mifepristone.  
 
Mifepristone is a safe and effective drug that was first approved by the FDA more than 20 years ago, has since been used by more than five million people in the U.S. to safely end their pregnancies, and is used in over half of all abortions in the United States.  
 
Below is a statement from Nicole Clegg, Interim CEO, Planned Parenthood Northern New England in response to today’s Supreme Court announcement:  

“Mifepristone is safe. Mifepristone is legal. And Mifepristone continues to be available to patients seeking abortion care at Planned Parenthood of Northern New England health centers in Maine, New Hampshire, and Vermont, and through our telehealth program.

 

“For more than 20 years, medication abortion has been an essential option for patients, has enabled access to abortion care at times when a health center visit was not an option, and has allowed patients to make private medical decisions.  
 
“While we will continue to follow the outcome of this Supreme Court case, rest assured that medication abortion is accessible and available in our region.” 

About the case: A group of anti-abortion activists and organizations sued the U.S. Food and Drug Administration (FDA) over its approval of mifepristone, one of two medications most commonly used in medication abortion in the United States. In the case that originated in Texas, Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration et al, the plaintiffs asked the court to order the FDA to rescind its approval of mifepristone from more than 20 years ago, in order to remove it from the market. On April 21st, the Supreme Court of the United States granted the stay requested by the Department of Justice (DOJ) and Danco in Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration et al. allowing mifepristone’s FDA approval to remain unchanged as the case proceeds through the Fifth Circuit Court of Appeals and the Supreme Court. This case will now be heard at the Supreme Court. 

 

For more information about this case and medication abortion, click here.   

 

About PPNNE

 Planned Parenthood of Northern New England (PPNNE) is the largest provider of reproductive and sexual health care across the state of Vermont. We serve Vermont residents through 7 health centers in Barre, Brattleboro, Burlington, Rutland, St. Johnsbury, White River Junction, and Williston. Last year we saw more than 16,000 patients at these sites. PPNNE was named a 2021 and 2022 Guardian of Excellence Award® winner by Press Ganey, the national leader in health care consumer and workforce engagement. Press Ganey recognizes PPNNE as a top-performing health care organization, achieving the 95th percentile or above for performance in patient experience, out of more than 20,000 medical practices.

Planned Parenthood cares about your data privacy. We and our third-party vendors use cookies and other tools to collect, store, monitor, and analyze information about your interaction with our site to improve performance, analyze your use of our sites and assist in our marketing efforts. You may opt out of the use of these cookies and other tools at any time by visiting Cookie Settings. By clicking “Allow All Cookies” you consent to our collection and use of such data, and our Terms of Use. For more information, see our Privacy Notice.

Cookie Settings

Planned Parenthood cares about your data privacy. We and our third-party vendors, use cookies, pixels, and other tracking technologies to collect, store, monitor, and process certain information about you when you access and use our services, read our emails, or otherwise engage with us. The information collected might relate to you, your preferences, or your device. We use that information to make the site work, analyze performance and traffic on our website, to provide a more personalized web experience, and assist in our marketing efforts. We also share information with our social media, advertising, and analytics partners. You can change your default settings according to your preference. You cannot opt-out of required cookies when utilizing our site; this includes necessary cookies that help our site to function (such as remembering your cookie preference settings). For more information, please see our Privacy Notice.

Marketing

On

We use online advertising to promote our mission and help constituents find our services. Marketing pixels help us measure the success of our campaigns.

Performance

On

We use qualitative data, including session replay, to learn about your user experience and improve our products and services.

Analytics

On

We use web analytics to help us understand user engagement with our website, trends, and overall reach of our products.